ALLMedicine™ Lymphoblastic Lymphoma Center
Research & Reviews 471 results
https://clinicaltrials.gov/ct2/show/NCT03384654
Aug 12th, 2022 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...
https://clinicaltrials.gov/ct2/show/NCT03914625
Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...
https://doi.org/10.1016/j.clml.2022.07.010
Clinical Lymphoma, Myeloma & Leukemia; Summers RJ, Teachey DT
Aug 9th, 2022 - While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. ...
https://clinicaltrials.gov/ct2/show/NCT04145531
Aug 5th, 2022 - This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL/LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to asse...
https://clinicaltrials.gov/ct2/show/NCT05303792
Aug 3rd, 2022 - PRIMARY OBJECTIVE: I. To compare undetectable measurable residual disease (MRD) event-free survival (EFS) rate of the experimental arm (A) to standard arm (B) with EFS defined as time from randomization to occurrence of an event. SECONDARY OBJECTI...
Drugs 5 results see all →
Clinicaltrials.gov 105 results
https://clinicaltrials.gov/ct2/show/NCT03914625
Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...
https://clinicaltrials.gov/ct2/show/NCT03384654
Aug 12th, 2022 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...
https://clinicaltrials.gov/ct2/show/NCT04145531
Aug 5th, 2022 - This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL/LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to asse...
https://clinicaltrials.gov/ct2/show/NCT05303792
Aug 3rd, 2022 - PRIMARY OBJECTIVE: I. To compare undetectable measurable residual disease (MRD) event-free survival (EFS) rate of the experimental arm (A) to standard arm (B) with EFS defined as time from randomization to occurrence of an event. SECONDARY OBJECTI...
https://clinicaltrials.gov/ct2/show/NCT00408005
Jul 28th, 2022 - PRIMARY OBJECTIVES: I. To determine, through randomization, the relative safety and efficacy of the addition of nelarabine (Compound 506U78) to augmented Berlin-Frankfurt-Münster (BFM) therapy (Regimen C, Children's Cancer Group [CCG]-1961). II. T...
News 45 results
https://www.onclive.com/view/bortezomib-improves-os-in-newly-diagnosed-t-cell-lymphoblastic-leukemia-and-lymphoma
Apr 18th, 2022 - The addition of bortezomib (Velcade) to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL), according to data from the phase 3 AALL1231 trial (NCT02112916) published in the J...
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types
Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19
Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient populati...
https://www.medpagetoday.com/hematologyoncology/othercancers/94225
Aug 26th, 2021 - Children and adolescents with cancer and SARS-CoV-2 infection were more likely to develop severe and critical cases of COVID-19 compared with the general pediatric population, according to a global cohort study. Of children with cancer who contrac...
https://www.medscape.com/viewarticle/954149
Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...